Chinese Obesity and Metabolic Surgery Database: Annual Report 2024

doi:10.3877/cma.j.issn.2095-9605.2025.02.001

Abstract

Abstract:

Objective

To analyze the status and number of metabolic and bariatric surgeries (MBS) in China in 2024.

Methods

Surgical volumes, procedure distribution, and workforce scale were estimated through integrated synthesis with multi-source data cross-validation, based on the Chinese Obesity and Metabolic Surgery Database (COMES Database). This study did not include data from the Hong Kong SAR, Macao SAR, and Taiwan region of China.

Results

190 hospitals were included in this study, covering 29 provinces (autonomous regions and municipalities) and 75 cities, with a total estimated 32 342 cases. It was also estimated that there were 970 hospitals in the country, with 1 430 bariatric surgeons and 800 case managers involved in MBS. The top three most performed MBS were sleeve gastrectomy (SG, 24 443 cases, 75.6%), Roux-en-Y gastric bypass (RYGB, 1 250 cases, 4.7%), one-anastomosis gastric bypass (OAGB, 1 234 cases, 3.8%), and 4 (0.017%) deaths reported.

Conclusions

The number of MBS decreased by 13.2% in 2024. The most performed procedures were SG, RYGB and OAGB. We should leverage the national "Weight Management Year" initiative to develop an integrated multidisciplinary care system for weight management. This requires strengthening standardized training programs, promoting multicenter clinical research, and enhancing international collaborations. Such efforts will advance the discipline’s sustainable development, elevate clinical standards, and expand its global standing.

Key words: Bariatric surgery, Metabolic surgery, Database, Annual report, Mortality, Case management

Chinese Society for Metabolic and Bariatric Surgery (CSMBS), Chinese Society for Integrated Health of Metabolic and Bariatric Surgery (CSMBS IH), Chinese Obesity and Metabolic Surgery Collaborative (COMES Collaborative). Chinese Obesity and Metabolic Surgery Database: Annual Report 2024[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(02): 85-91.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2025.02.001

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2025/V11/I02/85

Figures/Tables 2

References 20

[1]	NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults [J]. Lancet, 2024, 403(10431): 1027-1050.
[2]	杨华, 陈缘, 王存川, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库: 2019年度报告 [J/OL]. 中华肥胖与代谢病电子杂志, 2020, 6(3): 143-149.
[3]	杨华, 陈缘, 董志勇, 等. 中国肥胖代谢外科数据库: 2020年度报告 [J/OL]. 中华肥胖与代谢病电子杂志, 2021, 7(1): 1-7.
[4]	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库: 2021年度报告 [J/OL]. 中华肥胖与代谢病电子杂志. 2022, 8(1): 15-23.
[5]	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库: 2022年度报告 [J/OL]. 中华肥胖与代谢病电子杂志, 2023, 9(2): 83-91.
[6]	中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国医师协会外科医师分会肥胖代谢外科综合管理专家工作组, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库: 2023年度报告 [J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(2): 73-83.
[7]	Lin K, Mehrotra A, Tsai TC. Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management [J]. JAMA Network Open, 2024, 7(10): e2441380.
[8]	Tang S, Yu S, Wang C, et al. Factors Influence the acceptance of surgical treatment in chinese bariatric surgery candidates [J]. Obes Surg, 2018, 28(9): 2767-2773.
[9]	Fan M, Hong J, Cheung PN, Tang S, Zhang J, Hu S, et al. Knowledge and Attitudes Towards Obesity and Bariatric Surgery in Chinese Nurses [J]. Obes Surg, 2020, 30(2): 618-629.
[10]	Diao X, Gao L, Yang Y, et al. Knowledge and attitudes towards obesity and bariatric surgery in university students: a national survey [J]. Obes Surg, 2022, 32(9): 2869-2879.
[11]	Xiao N, Ding Y, Cui B, et al. Navigating obesity: A comprehensive review of epidemiology, pathophysiology, complications and management strategies [J]. The Innovation Medicine, 2024, 2(3): 100090.
[12]	Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial [J]. EclinicalMedicine, 2024, 69: 102475.
[13]	Brown A, Sergent H, Vu AH, et al. Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study [J]. Surg Endosc, 2025, Online ahead of print.
[14]	Çalık Başaran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels [J]. International Journal of Obesity, 2025, 49(3): 412-417.
[15]	Shin TH, Medhati P, Mathur V, et al. National trends in using revisional surgeries post-sleeve gastrectomy due to reflux and weight recurrence: a matched case-control analysis [J]. Surg Obes Relat Dis, 2025, 21(3): 240-246.
[16]	Liagre A, Martini F, Van Haverbeke O, et al. Ten-year outcomes of sleeve gastrectomy in a single-center series of 156 patients: weight loss and need of revisional surgery [J]. Am J Surg, 2025, 248: 116525.
[17]	国家卫生健康委办公厅. 国家卫生健康委办公厅关于禁止将"空肠回肠吻合术"应用于2型糖尿病治疗的通知 [EB/OL]. (2025-06-28) [2025-07-08]. URL
[18]	Au K, Zheng MH, Lee WJ, et al. Resmetirom and metabolic dysfunction-associated steatohepatitis: perspectives on multidisciplinary management from global healthcare professionals [J]. Curr Obes Rep, 2024, 13(4): 818-830.
[19]	Clyde DR, Adib R, Baig S, et al. An international Delphi consensus on patient preparation for metabolic and bariatric surgery [J]. Clin Obes, 2025, 15(2): e12722.
[20]	Yang W, Abbott S, Borg CM, et al. Global variations in preoperative practices concerning patients seeking primary bariatric and metabolic surgery (PACT Study): A survey of 634 bariatric healthcare professionals [J]. Int J Obes (Lond), 2022, 46(7): 1341-1350.

术式	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	%
RYGB	10	30	395	850	1 660	3 132	2 920	2 350	1 830	1 729	2 380	1 851	976	1 505	1 117	901	1 520	4.7
SG	10	30	60	165	240	777	2 200	3 221	4 201	5 119	6 233	7 386	10 669	19 846	25 642	30 352	24 443	75.6
OAGB	0	0	0	0	0	0	0	0	0	0	0	75	100	537	760	1228	1234	3.8
SG Plus	0	0	0	0	0	48	30	110	49	15	560	646	1064	1999	1618	2183	3021	9.3
AGB	97	220	185	135	45	36	0	1	0	0	0	0	7	1	1	0	5	0.0
Fundoplication	0	0	0	0	5	113	90	10	32	10	5	0	30	103	11	254	112	0.3
JIB/GIA	0	0	0	0	0	0	0	400	100	1 880	1 200	1 500	850	581	650	1 718	801	2.5
DS/SADI-S	0	0	0	0	0	0	0	0	0	0	0	10	145	311	6	99	102	0.3
Endoscopic	0	0	0	0	0	0	0	0	0	0	0	9	12	58	15	21	158	0.5
Revision	0	0	0	0	0	0	0	0	100	110	120	134	182	237	248	385	725	2.2
Other	0	0	0	0	0	0	0	0	28	79	77	89	2	30	3	108	221	0.7
TOTAL	117	280	640	1 150	1 950	4 106	5 240	6 092	6 340	8 942	10 575	11 700	14 037	25 208	30 071	37 249	32 342	100.0

术式	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	%
RYGB	10	30	395	850	1 660	3 132	2 920	2 350	1 830	1 729	2 380	1 851	976	1 505	1 117	901	1 520	4.7
SG	10	30	60	165	240	777	2 200	3 221	4 201	5 119	6 233	7 386	10 669	19 846	25 642	30 352	24 443	75.6
OAGB	0	0	0	0	0	0	0	0	0	0	0	75	100	537	760	1228	1234	3.8
SG Plus	0	0	0	0	0	48	30	110	49	15	560	646	1064	1999	1618	2183	3021	9.3
AGB	97	220	185	135	45	36	0	1	0	0	0	0	7	1	1	0	5	0.0
Fundoplication	0	0	0	0	5	113	90	10	32	10	5	0	30	103	11	254	112	0.3
JIB/GIA	0	0	0	0	0	0	0	400	100	1 880	1 200	1 500	850	581	650	1 718	801	2.5
DS/SADI-S	0	0	0	0	0	0	0	0	0	0	0	10	145	311	6	99	102	0.3
Endoscopic	0	0	0	0	0	0	0	0	0	0	0	9	12	58	15	21	158	0.5
Revision	0	0	0	0	0	0	0	0	100	110	120	134	182	237	248	385	725	2.2
Other	0	0	0	0	0	0	0	0	28	79	77	89	2	30	3	108	221	0.7
TOTAL	117	280	640	1 150	1 950	4 106	5 240	6 092	6 340	8 942	10 575	11 700	14 037	25 208	30 071	37 249	32 342	100.0

Please choose a citation manager

Content to export